ABSTRACT
G
liomas have heterogeneously infiltrative and proliferative features, among which glioblastoma multiforme (GBM) is the most common and has the worst prognosis in adults. 1 From a histopathologic standpoint, microvascular proliferation and/or necrosis is essential for the diagnosis of GBM. 1 However, random tissue sampling may not always lead to an accurate diagnosis because of tissue heterogeneity. Therefore, other diagnostic modalities to predict highly malignant regions, such as PET imaging, can provide complementary diagnostic and therapeutic information and guide selective target tissue sampling or resection.
Malignant tumor cells display an increased flux of glucose metabolism by increased expression of glucose transporters and hexokinase, as well as an increased rate of amino acid uptake and metabolism. 2 This increased transport and high metabolism oc-may be useful for an accurate diagnosis and establishment of effective therapeutic strategies for gliomas. Some clinical investigations by use of [ 18 F]fluoromisonidazole-PET have been recently undertaken to detect tissue hypoxia noninvasively in gliomas. [11] [12] [13] On the other hand, we previously reported the clinical usefulness of 62 Cu-diacetyl-bis(N 4 -methylthiosemicarbazone) ( 62 Cu-ATSM)-PET imaging for gliomas. 14 Our preliminary study revealed a relationship between 62 Cu-ATSM uptake values and hypoxia-inducible factor-1␣ expression, which is increased under hypoxia, 14 suggesting that 62 Cu-ATSM-PET is a practical hypoxic imaging technique in gliomas. However, whether 62 Cu-ATSM uptake is specific in GBM was not determined, and the correlation of 62 Cu-ATSM findings with FDG and MET remained unclear in GBM. In addition, to assess whether 62 Cu-ATSM uptake is dependent on BBB breakdown and to evaluate an additional value over MR imaging findings, we volumetrically and qualitatively compared 62 Cu-ATSM-PET imaging with T1-weighted MR imaging with Gd-DTPA. 
MATERIALS AND METHODS

Patients
Image Interpretation
Four board-certified nuclear medicine specialists who were unaware of the clinical information assessed the PET images semiquantitatively and volumetrically in consensus ( 62 Cu-ATSM and FDG, U.T. and T.I.; MET, R.M. and T.I.). MR imaging findings were also assessed by board-certified radiologists (U.T. and T.I.), who interpreted the tumors as either GBM or non-GBM gliomas. A volume of interest was outlined within areas of increased tracer uptake and was measured on each section. In extensively heterogeneous lesions, regions of interest covered all components. For semiquantitative interpretations, the standardized uptake value was determined by a standard formula. The tumor/background ratio (T/B ratio) of 62 Cu-ATSM and MET was calculated relative to the uptake in the contralateral frontal cortex. The FDG T/B ratio was calculated relative to the uptake in the contralateral white matter. The uptake values of the 62 Cu-ATSM, FDG, and MET tracers were determined by assessment of the maximum standardized uptake value (SUV max ) values and T/B ratios. Dr. View version R 2.5 for LINUX (Infocom, Tokyo, Japan) software was used to merge the PET images with the MR images, 4, 13, 14 and each PET and MR image was volumetrically compared. To evaluate volumetric analysis, we extracted the uptake regions of the 62 Cu-ATSM images on the basis of the optimal T/B ratio thresholds of Ն1.8, a cutoff value for predicting hypoxiainducible factor-1␣ expression in our previous study. 14 The uptake regions of the FDG and MET images were extracted on the basis of the T/B ratio thresholds of Ն1.5 and Ն1.3, respectively, in accordance with previous reports. 5, 9 These uptake regions were rated as metabolically active volumes. For GBM, we extracted the tumor volume by measuring a completely covered contrast-enhanced region with necrotic and cystic components on MR imaging. The contrast-enhanced volume was also separately extracted by measuring a contrast-enhanced region without any necrotic and cystic components. Metabolically active regions shown by each PET tracer were overlaid on the MR images for qualitatively comparing metabolically active regions among the 3 tracers. Tumors with 62 Cu-ATSM-active regions that demonstrated Յ50%
volumetric overlap with the active regions of FDG and MET were rated as heterogeneous with respect to intratumoral oxygenation. Correlations among 62 Cu-ATSM, FDG, and MET were also volumetrically analyzed. On the basis of the optimal cutoff value for prediction of GBM (T/B ratio, 1.9), which was defined by receiver operating characteristic analysis, tumors having 62 Cu-ATSM T/B ratios Ն1.9 were rated as GBM. The optimal cutoff threshold of the MET T/B ratio was set by receiver operating characteristic analysis, and tumors having MET T/B ratios Ն3.0 were rated as GBM. To assess the clinical value of 62 Cu-ATSM-PET findings relative to those of MET-PET and MR imaging findings for prediction of GBMs, we evaluated the positive and negative predictive values independently.
Statistical Analysis
All parameters were expressed as means Ϯ SDs. Two-way repeated measures ANOVA was used to compare the mean uptake values of each tracer. To determine the optimal radiotracer for prediction of GBM by semiquantitative analysis, we performed receiver operating characteristic analysis. 
RESULTS
Semiquantitative Analysis of PET Studies According to Tumor Classification
A summary of the uptake values for each PET tracer is presented in On-Line Table 2 . Representative images are shown in Fig 1 and in the On-Line Figure. The average 62 Cu-ATSM SUV max values in GBM and non-GBM gliomas were 1.68 Ϯ 0.94 and 0.98 Ϯ 0.52, respectively. The 62 Cu-ATSM SUV max was significantly higher for GBM than for non-GBM gliomas (P ϭ .03; Fig 2A) . A significant difference in SUV max was also detected between GBM and non-GBM gliomas for MET (5.23 Ϯ 1.11 and 3.25 Ϯ 1.66, respectively; P ϭ .02; Fig 2A) but not for FDG (7.31 Ϯ 3.22 and 5.72 Ϯ 2.25, respectively; P ϭ .18; Fig 2A) . The mean 62 Cu-ATSM T/B ratios in GBM and non-GBM gliomas were 3.10 Ϯ 2.37 and 1.47 Ϯ 0.57, respectively, which were also significantly different (P ϭ .03; Fig 2B) . Receiver operating characteristic analysis indicated that a 62 Cu-ATSM T/B ratio cutoff threshold of 1.9 was most predictive of GBM, with 90.0% sensitivity and 76.9% specificity (area under the curve, 0.88). Similar to the SUV max results, there was a significant difference in the T/B ratio between GBM and non-GBM gliomas for MET (3.53 Ϯ 0.70 and 2.27 Ϯ 0.97, respectively; P ϭ .01; Fig 2B) but not for FDG (2.71 Ϯ 1.56 and 2.44 Ϯ 1.28, respectively; P ϭ .65; Fig 2B) . Receiver operating characteristic analysis showed an optimal T/B ratio of 3.0 for MET (sensitivity, 83.3%; specificity, 76.9%; area under the curve, 0. 83, respectively), which was slightly less than that for 62 Cu-ATSM.
Volumetric and Qualitative Comparison among 3 Tracers in GBM
A summary of tumor volume and contrast-enhanced volume on MR imaging and the active volume for each PET tracer is presented in On-Line Table 3 . Table 1 
Volumetric Comparison with MR Imaging
The mean tumor volume and contrast-enhanced volume in GBMs were 45.4 Ϯ 26.5 and 21.6 Ϯ 14.3 cm 3 , respectively (Table 2) , which were significantly greater than those of the metabolically active volumes for 62 Cu-ATSM (P ϭ .002 and P ϭ .002, respectively) and FDG (P ϭ .002 and P ϭ .006, respectively). The mean active volume of MET was not significantly different from the mean tumor volume (P ϭ .56) and contrast-enhanced volume (P ϭ .06). 18; A) . The 62 Cu-ATSM and MET T/B ratios also show significant differences (P ϭ .03 and P ϭ .01), but no significant difference is observed in the FDG T/B ratio (P ϭ .65; B). *P Ͻ .05.
Predictive Values of
were detected in 63.2% (12/19) Cu-ATSM and MR imaging were 85.7% and 75.0%, respectively. On the other hand, when tested by the optimal cutoff threshold on MET (T/B ratio, 3.0), the positive and negative predictive values for a diagnosis of GBM were 83.3% and 60.0%, respectively. We found no significant correlation between 62 Cu-ATSM and MET (P ϭ .59).
DISCUSSION
Our present PET study demonstrated that 62 Cu-ATSM is a predictive radiotracer for GBM. Many clinical PET studies with FDG and MET have been conducted to discriminate among World Health Organization grades of gliomas. 4, 5, 7, 8 Several imaging studies have demonstrated the usefulness of FDG-PET in the differentiation between low-grade and high-grade gliomas and even between grade III and grade IV gliomas. 5, 7, 8 Because of the associated increased glucose uptake and high rates of glycolysis, FDG-PET shows high FDG uptake in GBM. 8 However, FDG-PET has a low signal-to-noise ratio in brain tumors, which is a result of the high glucose metabolism in normal brain tissue. 4 Moreover, because FDG uptake reflects an increased glycolytic rate in rapidly growing brain tumor cells even in grade II and III gliomas, 7,12 it may not be a suitable radiotracer to predict GBM. On the other hand, malignant gliomas demonstrate increased rates of amino acid uptake and metabolism. MET readily crosses the intact BBB through a neutral amino acid transporter and is incorporated into active tumor areas, which allows tumor visualization even in lowgrade gliomas. 9 In our current study, MET-PET revealed a significant difference between GBM and non-GBM despite the high frequency of oligodendroglial tumors. However, these oligodendroglial tumors are reported to show relatively high uptake of MET irrespective of their grade on MET-PET, 3, 4 19 Our preliminary clinical study also showed that 62 Cu-ATSM uptake values correlated highly with hypoxia-inducible factor-1␣ expression, which is a biomarker of tissue hypoxia, 14 and the optimal cutoff threshold to predict hypoxia-inducible factor-1␣ expression (T/B ratio, 1.8) was similar to that of our present study in the prediction of GBM (T/B ratio, 1.9). It has been well established that overexpression of hypoxia-inducible factor-1␣, a transcription factor that is part of the stress response mechanism, is initiated in the presence of low oxygen tensions and induces hypoxia-regulated molecules, such as vascular endothelial growth factor, glucose transporters, and carbonic anhydrase IX, 21 which correlate with treatment resistance and are highly expressed in GBM. 10 Therefore, 62 Cu-ATSM-PET may be a radiotracer useful in the identification of treatment-resistant hypoxic regions in patients with glioma. Our present study also demonstrated that hypoxic imaging by use of 62 Cu-ATSM for discrimination of GBM from non-GBM gliomas may be as effective as [ 18 F]fluoromisonidazole, 12 indicating that hypoxic imaging, including 62 Cu-ATSM, would be a better choice than FDG in the prediction of GBM. However, to our knowledge, correlations between hypoxic regions depicted by PET studies and high-uptake regions in FDG or MET have not been precisely studied in GBM. In our present study, we showed that 62 Cu-ATSM uptake in GBM correlates significantly with FDG by volumetric assessments, but half of the uptake regions were distributed heterogeneously. Under hypoxia, glycolysis is increased by hypoxia-inducible factor-1␣ activation, 21 whereas in malignant tumor cells, aerobic glycolysis is driven even under nonhypoxic conditions. 2 Therefore, FDG uptake might indirectly and partially reflect hypoxic regions as well as nonhypoxic regions. 22 In line with these observations, several clinical studies on lung and cervical cancers have directly compared 62 Cu-ATSM-PET with FDG-PET and suggested that intratumoral distribution and uptake values may be different, depending on the histopathologic type of the tumor. 15, 23 In addition, a previous study using a lung From a clinical point of view, MET-PET enables more accurate delineation of glioma extension than MR imaging, 6, 9 suggesting that MET is a practical radiotracer for the detection of infiltrative regions around contrast-enhanced regions on MR imaging, which can provide important clinical information for treatment. By combining 62 Cu-ATSM-and MET-PET imaging, delineation of hypoxic regions within MET-PET-active regions would provide additional value to delineate therapeutic targets as treatment-resistant hypoxic regions for more intensive therapy (ie, intensity-modulated radiation therapy and chemotherapy by use of convection-enhanced delivery as well as biopsy targets in GBM). However, the hypoxic mechanism is not fixed in time, and variability in spatial uptake can occur among repeated PET scans. 26 Therefore, it is crucial for PET imaging to elucidate the mechanism of changes in intratumoral radiotracer distribution as a clinical application. In addition, to confirm the differences among 62 Cu-ATSM, FDG, and MET in GBM, further precise metabolic evaluation within GBM is required. Among these available imaging modalities, it is not clear which is best for distinguishing GBM from non-GBM. Contrast enhancement on MR imaging might provide a simple index; however, it is sometimes ambiguous. 27 To compare diagnostic reliability, we compared positive and negative predictive values for MR imaging, MET-PET, and 62 Cu-ATSM-PET and showed that for the prediction of GBM, both were higher in 62 Cu-ATSM than in MR imaging, indicating that 62 Cu-ATSM-PET is a better imaging technique for the prediction of GBM than is MR imaging. In addition, the negative predictive value was also higher for 62 Cu-ATSM-PET (85.7%) vs MET-PET (60.0%), though the positive values were lower. This finding would suggest that combined assessment by use of 62 Cu-ATSM and MET may provide a more accurate diagnosis. However, because of the small number of patients in our present study, further clinical evaluation in a larger group of patients is required to confirm these hypotheses.
Study Limitations
One of the limitations of our study was that it is unknown how BBB disruption affects 62 Cu-ATSM kinetics. To gain some insight, we demonstrated that the 62 Cu-ATSM-active volumes in GBM were significantly less than those of the contrast-enhanced volumes on MR imaging, which are dependent on BBB breakdown accompanying neovascularization in gliomas. 6 Thus, it is suggested that 62 Cu-ATSM uptake would be determined by other factors in addition to BBB breakdown. Indeed, it has been shown that the oxygen pressure in GBM is relatively lower than the pressure in the surrounding cortex. 28 
CONCLUSIONS
The results of our study suggest that 62 Cu-ATSM-PET is predictive of GBM. In addition to the information obtained by FDG-PET, MET-PET, and MR imaging, 62 Cu-ATSM-PET may provide intratumoral hypoxic information useful in establishing targeted therapeutic strategies for patients harboring GBM.
